Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L

Therapy for treating cancer with an intratumoral or intravenous administration of a recombinant MVA encoding 4-1BBL (CD137L) and/or CD40L

US Patent 12390515 · Granted Aug 19, 2025

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination therapy for treating cancer with an antibody and intravenous adminis2023
Combination therapy for treating cancer with an antibody and intravenous adminis2023
Multivalent recombinant modified vaccinia virus ankara (MVA) vector encoding fil2022
Combination therapy for treating cancer with an intravenous administration of a 2022
Combination therapy for treating cancer with an intravenous administration of a 2022
Methods and compositions for enhancing vaccine immune responses2021
Recombinant modified vaccinia virus Ankara (MVA) multivalent filovirus immunogen2020
Methods and compositions for intra-nasal immunization with recombinant MVA encod2019
Compositions comprising apolipoprotein A polypeptide and interleukin 15, and met2014